Comparison of Saruplase and Alteplase in Acute Myocardial Infarction

Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of...

Full description

Saved in:

Bibliographic Details
Published in:	The American journal of cardiology Vol. 79; no. 6; pp. 727 - 732
Main Authors:	Bär, Frits W., Meyer, Jürgen, Vermeer, Frank, Michels, Rolf, Charbonnier, Bernard, Haerten, Klaus, Spiecker, Martin, Macaya, Carlos, Hanssen, Michel, Heras, Magda, Boland, Jean P., Morice, Marie-Claude, Dunn, Francis G., Uebis, Rainer, Hamm, Christian, Ayzenberg, Oded, Strupp, Gerhard, Withagen, Adrie J., Klein, Werner, Windeler, Jürgen, Hopkins, Gwyn, Barth, Hannes, von Fisenne, Michael J.M.
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 15-03-1997 Elsevier Elsevier Limited
Subjects:	Acetylsalicylic acid Angiography Angioplasty Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Catheters Coronary vessels Drug therapy Electrocardiography Heart attacks Heparin Intubation Medical imaging Medical sciences Myocardial infarction Pain Patients Pharmacology. Drug treatments Safety Thrombolysis Veins & arteries Netherlands Aachen Germany France Germany Spain Human Prognosis Infarct Acute Cardiovascular disease Saruplase Coronary heart disease Myocardial disease Chemotherapy Alteplase Treatment Myocardium Complication Comparative study Fibrinolytic
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Four hundred seventy-three patients with acute myocardial infarction (AMI) were treated with either saruplase (80 mg/hour, n = 236) or alteplase (100 mg every 3 hours, n = 237). Comedication included heparin and acetylsalicylic acid. Angiography was performed at 45 and 60 minutes after the start of thrombolytic therapy. When flow was insufficient, angiography was repeated at 90 minutes. Coronary angioplasty was then performed if Thrombolysis In Myocardial Infarction (TIMI) trial 0 to 1 flow was seen. Control angiography was at 24 to 40 hours. Baseline characteristics were similar. Angiography showed comparable and remarkably high early patency rates (TIMI 2 or 3 flow) in both treatment groups: at 45 minutes, 74.6% versus 68.9% (p = 0.22); and at 60 minutes 79.9% versus 75.3% (p = 0.26). Patency rates at 90 minutes before additional interventions were also comparable (79.9% and 81.4%). Angiographic reocclusion rates were not significantly different: 1.2% versus 2.4% (p = 0.68). After rescue angioplasty, angiographic reocclusion rates of 22.0% and 15.0% were observed. Safety data were similar for both groups. Thus, (1) early patency rates were high for saruplase and alteplase treatment, (2) reocclusion rates for both drugs were remarkably low, and (3) complication rates were similar. Thus, saruplase seems to be as safe and effective as alteplase. In the SESAM trial, saruplase or alteplase was given to 473 patients with acute myocardial infarction. Angiography at 45 minutes already showed high patency rates (Thrombolysis in Myocardial Infarction trial 2 or 3 flow) with saruplase and alteplase of 74.6% and 68.9%, at 60 minutes 79.9% and 75.3%, and at 90 minutes (before intervention) 79.9% and 81.4%, respectively. Angiographic reocclusion rates at 24 to 40 hours were low: 1.2% and 2.4% (p = 0.68). Safety data were comparable. Thus, both saruplase and alteplase treatment resulted in high, early patency, and low reocclusion rates.
ISSN:	0002-9149 1879-1913
DOI:	10.1016/S0002-9149(97)89274-0